Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-13

Clinical Trial Update: Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is recruiting to evaluate the transmural healing and disease-modifying effects of guselkumab in Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Guselkumab (guselkumab)

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Crohn's Disease | Phase 3 | Status: RECRUITING